21 August 2019 - NHS England has commissioned Roche and Chugai’s joint haemophilia A drug, Hemlibra (emicizumab), agreeing to fund the drug for around 2,000 people in the country who live with the condition.

The companies announced that the drug will be reimbursed for people with severe congenital haemophilia A without factor VIII inhibitors, following NHS England’s decision to routinely fund the product for all haemophilia A patients with factor VIII inhibitors in July 2018.

The ‘life-changing’ treatment dramatically cuts the risk of life-threatening bleeds and reduces treatment time, and will be available as part of a package of measures set out in the NHS Long Term Plan which will save lives through access to the most advanced medical interventions.

Read Pharma Times article